Background/Aims Creatinine clearance (CL) is used to assess glomerular filtration rate (GFR). During the clinical development of dronedarone, a new antiarrhythmic agent, a 10–15% increase in serum creatinine was noticed, as also shown recently for amiodarone. This study aimed to assess dronedarone effects on renal function and tubular cations handling. Methods 12 healthy males were enrolled in a randomised, cross-over, placebo-controlled, double-blind study. They received 400mg dronedarone or placebo bid for 7 days. Baseline and on-treatment renal function tests were performed under strict standardization of intakes, by assessing creatinine, sinistrin, para-amino-hippurate (PAH) and N-methylnicotinamide (NMN) CLs, and electrolyte excretions. Results Dronedarone did not alter sinistrin CL compared to placebo, but decreased creatinine CL significantly (mean 138 to 119mL/min under dronedarone vs 142 to 149 under placebo; p=0.04) and NMN CL marginally (448 to 368 vs 435 to 431; p=0.06), while PAH CL and other renal parameters remained unaffected. Conclusion Dronedarone compared to placebo reduces renal creatinine and NMN CLs by about 17%, without evidence of a true effect on GFR, renal plasma flow or electrolyte exchanges. This suggests a specific inhibition of tubular organic cation transporters (OCT). A limited increase in serum creatinine is therefore expected under dronedarone treatment, but does not mean a decline in renal function. Clinical Pharmacology & Therapeutics (2005) 77, P10–P10; doi: 10.1016/j.clpt.2004.11.041
Read full abstract